Clinical trial NCT03239457 - References

Diabetic Foot — Efficacy and Safety of Heberprot-P® in Patients With Advanced Diabetic Foot Ulcer in Dasman Diabetes Institute.

Citation(s)

•   Boulton AJ, Kirsner RS, Vileikyte L
  Clinical practice. Neuropathic diabetic foot ulcers. N Engl J Med. 2004 Jul 1;351(1):48-55. Review.
•   Brem H, Sheehan P, Boulton AJ
  Protocol for treatment of diabetic foot ulcers. Am J Surg. 2004 May;187(5A):1S-10S. Review.
•   Brown GL, Curtsinger L 3rd, Brightwell JR, Ackerman DM, Tobin GR, Polk HC Jr, George-Nascimento C, Valenzuela P, Schultz GS
  Enhancement of epidermal regeneration by biosynthetic epidermal growth factor. J Exp Med. 1986 May 1;163(5):1319-24.
•   Cohen S, Carpenter G, King L Jr
  Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem. 1980 May 25;255(10):4834-42.
•   Cohen S, Carpenter G, King L Jr
  Epidermal growth factor-receptor-protein kinase interactions. Prog Clin Biol Res. 1981;66 Pt A:557-67.
•   Cohen S, Carpenter G
  Human epidermal growth factor: isolation and chemical and biological properties. Proc Natl Acad Sci U S A. 1975 Apr;72(4):1317-21.
•   COHEN S
  Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem. 1962 May;237:1555-62.
•   Dinh TL, Veves A
  A review of the mechanisms implicated in the pathogenesis of the diabetic foot. Int J Low Extrem Wounds. 2005 Sep;4(3):154-9. Review.
•   Eldor R, Raz I, Ben Yehuda A, Boulton AJ
  New and experimental approaches to treatment of diabetic foot ulcers: a comprehensive review of emerging treatment strategies. Diabet Med. 2004 Nov;21(11):1161-73. Review.
•   Frykberg RG, Zgonis T, Armstrong DG, Driver VR, Giurini JM, Kravitz SR, Landsman AS, Lavery LA, Moore JC, Schuberth JM, Wukich DK, Andersen C, Vanore JV; American College of Foot and Ankle Surgeons
  Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg. 2006 Sep-Oct;45(5 Suppl):S1-66.
•   Gospodarowicz D
  Epidermal and nerve growth factors in mammalian development. Annu Rev Physiol. 1981;43:251-63. Review.
•   Gross I, Dynia DW, Rooney SA, Smart DA, Warshaw JB, Sissom JF, Hoath SB
  Influence of epidermal growth factor on fetal rat lung development in vitro. Pediatr Res. 1986 May;20(5):473-7.
•   Lavery LA, Armstrong DG, Murdoch DP, Peters EJ, Lipsky BA
  Validation of the Infectious Diseases Society of America's diabetic foot infection classification system. Clin Infect Dis. 2007 Feb 15;44(4):562-5. Epub 2007 Jan 17.
•   Lipsky BA
  Medical treatment of diabetic foot infections. Clin Infect Dis. 2004 Aug 1;39 Suppl 2:S104-14.
•   Reiber GE, Vileikyte L, Boyko EJ, del Aguila M, Smith DG, Lavery LA, Boulton AJ
  Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care. 1999 Jan;22(1):157-62.
•   Reiber GE
  The epidemiology of diabetic foot problems. Diabet Med. 1996;13 Suppl 1:S6-11. Review.
•   Simmons Z, Feldman EL
  Update on diabetic neuropathy. Curr Opin Neurol. 2002 Oct;15(5):595-603. Review.
•   Wild S, Roglic G, Green A, Sicree R, King H
  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004 May;27(5):1047-53.
•   Williams DT, Hilton JR, Harding KG
  Diagnosing foot infection in diabetes. Clin Infect Dis. 2004 Aug 1;39 Suppl 2:S83-6.

Efficacy and Safety of Heberprot-P® in Patients With Advanced Diabetic Foot Ulcer in Dasman Diabetes Institute. Demonstrative Study

Details for clinical trial NCT03239457